Blog

Arabic Numerals?

Frequent FF contributor Dave McGlasson, MS, MLS posted this comment in LinkedIn on 9/7/23. “I have noticed at recent meetings and in some journal articles that coagulation factors are sometimes referred to in Arabic instead of Roman numerals. For example F8 instead of FVIII. Has this been officially proposed as a change by any standardization […]

Welcome Rutgers Graduate Students

Colleges, universities, medical schools, residencies, and fellowships are welcome to review and comment on our entries and services and take advantage of our Educational Modules. Beginning today, August 31, 2023, we salute 20 or more Rutgers University graduate students enrolled in CLSC 5124; Advanced Hemostasis. Our students are in Rutgers’ Masters in Clinical Laboratory Science […]

September 2023 Cheat Sheet

Here is your September 2023 Cheat Sheet, a copy of which will land in your mailbox within a few days. The Cheat Sheet introduces and reviews our Quick Question series, links to our August entries, and announces upcoming events. Enjoy!

Organizational Name Changes

Like Ye, the artist formerly known as Kanye, several hemostasis-related organizations have changed their names… In 2005 The American Association of Blood Banks changed its name to a simple “AABB.” However, as of 2021, AABB is the Association for the Advancement of Blood & Biotherapies [AABB]. In August of 2023, the American Association for Clinical […]

Follow-up to “FDA Approves Hemophilia A Gene Transfer Therapy”

This is a follow-up to “FDA Approves Hemophilia A Gene Transfer Therapy,’ posted July 3, 2023, with reference to Dr. Emmanuel Favaloro’s comment, added August 9 and citing Valentino LA, Kaczmarek R, Pierce GF, et al. Hemophilia gene therapy: first, do no harm. J Thromb Haemost. 2023: S1538-7836(23)00501-9. doi: 10.1016/j.jtha.2023.06.016. [click for a copy]. The […]

Bleeding Disorders

August 2023 Quick Question: Coag Specimen Hemolysis

Our August 2023 Quick Question asks, How do you distinguish ex vivo from intravascular plasma hemolysis? The question arises from our lengthy July 25, 2023 discussion, DIC and hemolysis, and is a poll; there is no wrong answer. Read the comments section featuring hemostasis experts Dave McGlasson, Dr. Emmanuel Favaloro, Dr. Giuseppe Lippi, and Robert […]

Quick Question Archive

June 2023 Cheat Sheet

Here is a copy of your June 2023 cheat sheet. Your personal copy will arrive by email in a few days.

June 2023 Quick Question: Factor VIII Inhibitor Bypass

Our June Quick Question asks, “Name the bispecific antibody-based FVIII inhibitor bypass agent,” and lists several recently released therapeutics that are changing the shape of hemostasis disorder treatment. Please select your answer from the column on the right and add your comments below.

Quick Question Archive

May 2023 Quick Question: DTI

Our May 2023 Quick Question asks, “Which DOAC is a direct thrombin inhibitor? Our 70 respondents chose… Dabigatran [Pradaxa]: 56 [80%] Rivaroxaban [Xarelto]: 3 [4%] Apixaban [Eliquis]: 3 [4%] Warfarin [Coumadin]: 7 [10%] Clopidogrel [Plavix]: [2%] Dabigatran is the direct thrombin inhibitor, whereas rivaroxaban and apixaban are direct anti-Xa inhibitors. Clopidogrel is an antiplatelet antithrombotic. […]

Quick Question Archive

Webinar: The Many Faces of VWF, Part 2: Tumor Progression

Fritsma Factor participants, we invite you to view the next installment of our video series “Coag Conversations:” Dr. E. J. Favaloro: The Many Faces of von Willebrand Factor; or Von Willebrand Factor, ADAMTS13, Malignancy, and Beyond Part 2: Von Willebrand Factor and ADAMTS13: Tumor Progression and Beyond, sponsored by BioMedica Diagnostics, Inc.

Load more

George Fritsma is a medical laboratory scientist, educator, and author. George holds faculty appointments with Rutgers University and Michigan State University, and is a member of the International Society on Thrombosis and Hemostasis, American Association of Clinical Chemists, and American Society for Clinical Laboratory Science.

Cheat Sheets from George

Quick Question